The Latest Breaking News from Sage

Over the past 3 months, 7 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

  Sage Therapeutics (NASDAQ:SAGE) reported its Q1 earnings results on Tuesday, May 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Businesses involved in deals across the region include RSA Insurance, Roman Ltd, Tait Walker and ReViral

Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc (NASDAQ:BIIB) have initiated a rolling submission of a marketing application to the FDA for zuranolone in major depressive disorder (MDD).  Zuranolone is an investigational two-week, once-daily oral drug developed for MDD and postpartum depression (PPD).  The companies have submitted the nonclinical module and plan to submit the remaining…

Judges said the Tory Government failed to consider the risks from asymptomatic transmission when they allowed hospital patients to be discharged to care homes

Hitting the right note - recruitment drive seeks 16 to 30-year-olds for new choir Voices of the River's Edge to sing in a BBC Proms first

Chief executive Steve Hare said the brand refresh 'isn’t just a change of the symbol– it’s a symbol of change' as it seeks to help SMEs as much as possible

Sage says the acquisition supports its drive to help non-profit and faith-based organisations manage programmes that involve a revolving loan fund

We told you earlier this year how 15 dogs died at Shawfield stadium over a three year span

  Sage Therapeutics (NASDAQ:SAGE) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.

An MSP has said he believes it is an industry that is "beyond reform"/